Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2022 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Extends Cash Runway to Mid-2024 Commenced Dosing in Phase 1 Clinical Trial of TN-301; Data Expected in 2023 Plans to Submit TN-201 IND by Year End SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 ...
November 04, 2022 08:00 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
October 04, 2022 08:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
September 29, 2022 08:00 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
September 29, 2022 07:45 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
September 06, 2022 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
September 06, 2022 08:00 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative...
August 10, 2022 16:01 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and...
July 06, 2022 14:00 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure

Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with...